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Abstract
Post-translational modification (PTM) plays a crucial role in biological functions and corresponding disease
developments. Discovering disease-associated non-synonymous SNPs (nsSNPs) altering PTM sites can help to
estimate the various PTM candidates involved in diseases, therefore, an integrated analysis between SNPs, PTMs
and diseases is necessary. However, only a few types of PTMs affected by nsSNPs have been studied without
considering disease-association until now. In this study, we developed a new database called PTM-SNP which
contains a comprehensive collection of human nsSNPs that affect PTM sites, together with disease information.
Total 179,325 PTM-SNPs were collected by aligning missense SNPs and stop-gain SNPs on PTM sites (position 0) or
their flanking region (position -7 to 7). Disease-associated SNPs from GWAS catalogs were also matched with
detected PTM-SNP to find disease associated PTM-SNPs. Our result shows PTM-SNPs are highly associated with
diseases, compared with other nsSNP sites and functional classes including near gene, intron and so on. PTM-SNP
can provide an insight about discovering important PTMs involved in the diseases easily through the web site.
PTM-SNP is freely available at http://gcode.kaist.ac.kr/ptmsnp.
Introduction
Since the advance of next-generation sequencing (NGS)
technologies, the number of single nucleotide poly-
morphisms (SNPs) keeps increasing precipitously and it
becomes crucial issue to discovering functional implica-
tion of SNPs on the biological process and complex dis-
eases. Especially, non-synonymous SNPs (nsSNPs),
including missense SNPs that provoke amino acid muta-
tion and stop-gain SNPs that terminate the peptide
synthesis by generating stop codon, are thought to play
key roles in causing diseases by changing the protein
structure and functions. It is estimated that nsSNPs
cover more than half of the disease-causing mutation in
the Human Gene Mutation Database [1].
In this regard, several efforts have been made to eluci-
date the effect of nsSNPs on diseases recently. For
example, CanPredict [2] and Diseasome [3] tried to pre-
dict the effect of nsSNPs on disease using SIFT [4] or
PolyPhen [5]. However, although previous studies pre-
dicted disease-associated nsSNPs, related biological pro-
cess have not been provided and hence have limits to
understand detailed disease mechanisms. Therefore, an
additional in-depth study about correlation between the
location of nsSNPs and functional site of proteins is
necessary. David et al. reported that disease-associated
nsSNPs in the protein interaction interface affect the
protein stability and prohibit protein interactions [6].
Alternatively, post-translational modification (PTMs)
sites are another important functional parts of the pro-
tein and nsSNP influencing PTM sites should be
considered.
Post-translational modification plays essential roles in
the most biological pathways and disruption of PTM sites
is known as the major cause of diseases [7]. Radivojac,
et al. predicted phosphorylation-related variants from
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disease-associated variants and found that phosphoryla-
tion binding site disrupting variants are correlated with
somatic cancer mutations [8]. Recently, several previous
studies [9-11] detected PTM-related nsSNPs or protein
sequence variations. Yang et al. [9] collected 15,738
experimental phosphorylation binding sites and found
1,515 coding-region SNPs in the flanking phosphoryla-
tion binding sites with position -7 to +7. Ryu et al. [10]
collected 33,651 protein-sequence variations from the
SwissVariant database and predicted the effects of var-
iants on phosphorylation binding sites using a phos-
phorylation-related variant prediction tool. Ren et al.
[11] collected 91,797 nsSNPs from dbSNP Build 130
and mapped nsSNPs onto mRNA/Protein sequences
from RefSeq Build 31 [12]. They collected 64,035 phos-
phorylation-related nsSNPs in 5 categories using GPS
2.0 [13], a phosphorylation binding site prediction tool.
However, previous studies are tend to focus on phos-
phorylation even there exists other kinds of PTMs like
ubiquitination that is related in protein degradation
[14]. They also didn’t consider the statistical significance
with disease-association of PTM-SNPs with genome-
wide association studies.
Here, we built a comprehensive PTM-SNP database
containing more than 50 kinds of experimentally vali-
dated PTMs and predicted PTMs. While previous studies
considered phosphorylation, PTM-SNP can examine
multiple PTMs simultaneously. We also matched PTM-
SNPs with various disease-associated SNPs based on
GWAS to find disease-associated PTM-SNPs. The statis-
tical significance values of the disease-association from
GWAS are provided for accurate consideration of dis-
ease-association. We found that PTM-SNPs are highly
correlated with diseases, compared with other SNPs in
functional units. In addition, the result of the case study
about PTM-SNP on type 2 diabetes shows our PTM-
SNP provides an insight into unveiling important PTMs
involved in causing diseases and finding novel disease
markers. The web interface of PTM-SNP make easier to
access our data and be conjugated as useful evidences in
biomedical studies like drug development or predicting
diagnosis and drug response.
Materials and methods
Collection of nsSNP data and PTM site data
We collected total 517,466 human nsSNPs from the
NCBI dbSNP database Build 135 [15]. From 517,466
nsSNPs, 509,183 SNPs were missense SNPs and 14,878
SNPs were stop-gain (nonsense) SNPs. We linked the
location of nsSNPs on protein sequences from Ref-Seq
Build 37.3. The flanking peptide of nsSNP sites from -7
to +7 retrieved by using the SNP-MapLinkProtein table
in dbSNP and defined as the SNP sequence.
Human PTM site data were retrieved from dbPTM3
[16], which includes 194,886 experimentally verified
PTMs from MS/MS analysis based research articles and
10 external PTM-related resources. The dbPTM also
provides 404,501 computationally predicted PTMs by
the KinasePhos-like method based on hidden Markov
models (HMMs). It includes 20 types of PTM sites pre-
dicted with the threshold of specificity 100% for mini-
mizing false positive. Peptides of flanking PTM sites
from -7 to +7, called the PTM site sequence, were
retrieved by matching the PTM site with the protein
sequence from UniProt [17].
Detection of PTM-SNP
PTM-SNPs were detected by aligning the SNP sequence
with the PTM site sequence because not all sequences
in UniProt and RefSeq are perfectly identical (end-to-
end identical). Each residue in the SNP sequence is
matched with the PTM site sequence by sliding one-by-
one (Figure 1). The PTM-SNP is defined as the nsSNP’s
position of the best-aligned SNP sequence with the
PTM site sequence. As Figure 1 illustrates, an SNP
sequence of nsSNP, rs1803573, is aligned well with the
+3 residue of the PTM site sequence. In few cases, mul-
tiple hits with diverse locations were detected due to
sequence repeats. The European Molecular Biology
Open Software Suite (EMBOSS) [18] Needle, a global
pairwise sequence alignment tool, was applied to handle
these exceptional cases.
We also extracted and integrated PTM-SNPs from the
public resource, PhosSNP 1.0. PhosSNP includes phos-
phorylation-associated nsSNP from computationally
translating mRNA sequences. However, about 18% of
SNPs in PhosSNP have not yet been defined as nsSNP
by dbSNP Build 135, therefor, were removed in the inte-
grating process.
Disease-associated PTM-SNPs
From GWASs using SNP arrays and NGS techniques,
huge numbers of statistically significant disease-asso-
ciated SNPs have been identified recently. National
Human Genome Research Institute (NHGRI) GWAS cat-
alog have been provided 8,771 trait-associated SNPs with
p-values < 1.0 × 10-5 (Apr 02, 2013) [19]. The genetic
association database (GAD) [20] contains 29,578 disease-
associated SNPs and 23,671 disease-associated SNPs are
also available from Genotypes and Phenotypes (dbGaP)
[21]. To find a correlation between PTM-SNPs and dis-
eases, we collected total 52,731 distinct disease-associated
SNPs from NHGRI GWAS catalog, GAD and dbGaP
after then matched these SNPs with our PTM-SNPs.
Furthermore, we analyzed type 2 diabetes (T2D) asso-
ciated SNPs that were identified in our previous study [22]
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by using Wellcome Trust Case Control Consortium
(WTCCC) datasets [23]. T2D-associated SNPs with
p-values < 1.0 × 10-5 were identified from quality con-
trolled (QC) 409,656 SNPs, based on Cochran-Armitage
trend test statistics using PLINK 1.07 [24]. QC is applied
as a sample missing genotype rate of > 3%, a SNP missing
genotype rate of > 1%, Hardy-Weinberg Equilibrium
(HWE) p-value ≤ 10-4, and minor allele frequency (MAF)
< 1%. Linkage disequilibrium pruning was leaved out to
preserve the PTM-SNP candidates. T2D PTM-SNPs were
detected by mapping T2D-associated SNPs and PTM-
SNPs. Significantly associated T2D PTM-SNPs were
further studied to interpret disease mechanisms with var-
ious biological information resources. Known disease
genes are mainly collected from OMIM [25], GAD, and
KEGG [26]. Drug targets are collected from DrugBank
[27], PharmGKB Drug [28], and KEGG Drug.
Result and disscussion
Data Statistics
PTM-SNP were collected by integrating dbPTM-dbSNP
matching and PhosSNP 1.0. Totally, distinct 179,325
PTM-SNPs were identified, consisting of 133,266 PTM-
SNPs from dbPTM-dbSNP matching and 64,035 PTM-
SNPs from PhosSNP. All PTM-SNPs were categorized
into 3 groups based on the SNP position; PTM-SNPs on
PTM site (position 0), PTM-SNPs flanking PTM sites
(position -7 to 7), and stop-gain PTM-SNPs (Table 1).
We also categorized PTM-SNPs based on PTM types.
Table 2 shows the top 10 PTMs which have high PTM-
SNP ratio (All PTMs are listed in the additional file 1).
From the 599,382 PTM sites in dbPTM3, 48.45% were
related with at least one PTM-SNP. Especially, the result
represents that PTM types involved in the signal trans-
duction, such as phosphorylation, ubiquitination, and
acetylation-sites, have a greater proportion of PTM-
SNPs than other PTM types. The proteolytic cleavage
sites and disulfide bond-sites also have a higher propor-
tion of PTM-SNP where they can change protein struc-
ture dramatically.
Correlation between PTM-SNP and Diseases
To elucidate the disease mechanism from PTM perspec-
tive, we matched PTM-SNPs with disease-associated
SNPs. To estimate the importance of PTM-SNP on
causing diseases, we compared the coverage rate of dis-
ease-associated SNPs between PTM-SNPs with other
missense and stop-gain SNPs not related with PTM
sites (Table 3). Total 281 disease-associated SNPs in
NHGRI GWAS catalog was applied in the comparison
and 186 of them were identified as PTM-SNPs. As a
result, the coverage ratio of disease-associated PTM-
SNP was more than four times than the ratio of non
PTM-SNP. Although the coverage ratio is too low
because the number of disease-associated SNPs are too
small than the number of SNPs, p-values calculated by
fisher’s exact test shows our result is significantly asso-
ciated with the disease.
Not only missense and stop-gain SNPs, we also com-
pared different functional SNPs in dbSNP. Functional
classes that contain more than 100 disease-associated
SNPs were considered in comparison. In addition,
Figure 1 Detection of a PTM-SNP by alignment of a PTM site sequence and a SNP site sequence. Start from -7 to 7 residues of PTM site
sequences, each residue is matched with nsSNP site of the SNP sequence by sliding one-by-one. From the best aligned position of SNP
sequence, the location of PTM-SNP is identified as the location of the PTM site sequence that is aligned with the nsSNP.
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414,510 SNPs on miRNA-mRNA binding site were col-
lected from MirSNP [29]. The result shows that SNPs
near the gene, such as NearGene-3, MirSNP, NearGene-
5 and UTR-3 were higher disease-associated proportion
than SNPs in intron because they might affect protein
functions by indirect way like regulating protein expres-
sions. On the other hand SNPs around PTM site can
give a potent influence on the protein and, as a result,
the ratio of disease-associated PTM-SNP was superior
to other functional classes. Therefore, we can conclude
that PTM-SNPs are highly associated with diseases com-
pared with both other nsSNPs and other functional
sites.
Table 4 demonstrates the statistics of disease-asso-
ciated SNPs based on PTM categories. Eight PTM types
contains at least one disease-associated SNPs from the
NHGRI GWAS catalog. The result shows phosphoryla-
tion is highly significant with disease association while it
Table 1. PTM-SNP statitsics based on SNP locations
Post-translational Modification dbPTM-dbSNP matching PhosSNP PTM-SNP
Experimental Predicted Experimental Predicted
On the PTM site 4,385 5,098 172 16,954 26,100
On the flank of the PTM site 52,249 76,654 1,836 59,340 163,254
Stop-gain affected PTM site 7,757 10,432 48 442 11,940
Total 60,380 88,181 2,004 6,4035 179,325
Table 2. Statistics of PTM Site based on PTM types with the Top 10 ratio
Post-translational Modification Number of PTM sites Number of PTM Sites of PTM-SNPs Ratio
Disulfide bond 1,750 1,230 0.703
Ubiquitination 34,507 21,824 0.633
Proteolytic Cleavage 1,569 987 0.629
Acetylation 11,612 6,760 0.582
Phosphorylation 355,203 203,830 0.574
Sumorylation 1,180 673 0.570
S-nitrosylation 1,286 695 0.540
N-linked Glycosylation 65,121 21,215 0.326
Methylation 6,166 1,761 0.286
Sulfation 8,614 2,433 0.282
O-linked Glycosylation 91,678 21,335 0.233
Other PTMs 20,696 7,670 0.371
Total 599,382 290,413 0.485
Table 3. Statistics of disease-associated SNPs based on Functional Categories
Functional classification Number of SNPs Number of Disease-associated SNPs Coverage Ratio P-value
Missense & Stop-gain (PTM-SNP) 179,325 186 0.00114 2.72E-67
NearGene-5 744,086 251 0.00033 7.59E-13
UTR-3: MirSNP 414,510 151 0.00036 2.76E-10
UTR-3 513,249 170 0.00033 1.61E-08
NearGene-3 189,105 71 0.00037 2.54E-06
UTR-5 80,250 35 0.00043 3.33E-05
Cds-synon 312,479 100 0.00032 4.54E-05
Missense & Stop-gain (Non PTM-SNP) 361,401 95 0.00026 0.014
Intergenic 20,492,263 4,357 0.00021 0.136
Frameshift 30,578 5 0.00016 0.768
Intron 19,248,959 3,678 0.00019 0.999
Total SNPs 41,740,143 8,771 0.00021 -
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has a p-value lower than 0.05. Table 5 demonstrates the
statistical analysis of trait or disease-associated PTM-
SNPs (Whole statistics are listed in additional file 2).
Disease-associated SNPs were collected from the
NHGRI GWAS catalog, GAD, and dbGaP to match
with PTM-SNPs. From the statistical analysis of disease-
associated PTM-SNPs and disease-associated SNPs for
top-ranked diseases, complex diseases, such as coronary
heart disease and T2D are highly correlated with PTM-
SNPs.
Case Study for Type 2 Diabetes associated PTM-SNP
Among the top-ranked diseases with disease-associated
PTM-SNPs, T2D was selected for an in-depth analysis.
T2D-associated PTM-SNPs were collected not only from
GWAS catalog, GAD and dbGaP but also by mapping
PTM-SNPs and 456 T2D-associated SNPs within the p-
value threshold 1.0 × 10-5 extracted from our previous
study. Table 6 shows T2D-associated PTM-SNPs, includ-
ing PTM name, p-value, gene name, and matching result
with known T2D genes from public disease gene data-
bases. In total, 6 T2D-associated PTM-SNPs are detected
in 5 genes; PCSK1, C6orf57, WFS1, PPARG, and KCNJ11.
Among them, WFS1, PPARG, and KCNJ11 are known
T2D genes and were identified in T2D related functional
modules such as glucose homeostasis (GO:0042593).
PCSK1 is associated with obesity and diabetic nephropathy
from previous GWASs and could be a T2D candidate
gene.
One of T2D-associated PTM-SNPs, rs1801282, is
located on PPARG which is a popular T2D gene and a
T2D drug target for a thiazolidinedione and changed the
Pro12 to the alanine. The SNP is reported T2D from pre-
vious study [30], however, the detailed correlation
between the SNP and T2D have not been clearly known
yet. According to PTM-SNP, rs1801282 may enhance the
phosphorylation on Ser8 by CSNK2A1, prohibit the
phosphorylation on Ser14 by MTOR or MAPK10, and
also may affect the phosphorylation on Ser16. Not only
PPARG but CSNK2A1, MAPK10, and MTOR are known
as T2D genes and participate on parts of T2D associated
pathways such as type II diabetes mellitus, insulin signal-
ing pathway, and Wnt signaling pathway in KEGG.
The associations with T2D, body mass index (BMI),
and weight of a Val66Met PTM-SNP (rs6265) located on
BDNF are discovered from NHGRI GWAS catalogs and
WTCCC T2D dataset analysis. The association between
obesity and diabetes is discovered with rs6265 due to
GWASs on BMI, weight, and T2D identified G allele as a
risk allele and A allele as a non-risk allele. Adjacent site
Thr62 of BDNF is predicted as a phosphorylation site
and kinases for Thr62 are predicted as ARAF, RAF1,
Table 4. Statistics of disease-associated SNPs based on PTMs
Post-translational Modification Number of Disease Associated PTM-SNP Number pf Total PTM-SNP P-value
Phosphorylation 179 165489 0.021
Proteolytic Cleavage 2 1145 0.333
Disulfide bond 2 1253 0.373
S-palmitoyl Cysteine 1 1797 0.846
N-linked Glycosylation 7 9400 0.860
O-linked Glycosylation 3 5925 0.947
Acetylation 1 5579 0.997
Ubiquitination 4 15862 0.999
Table 5. Statistics of trait or disease-associated PTM-SNPs from GWAS catalogs
Disease Number of SNP Number of PTM-SNP Ratio
Coronary heart disease 122 7 0.057
Diabetes Mellitus, Type 1 293 11 0.038
Lupus Erythematosus, Systemic 345 11 0.032
Diabetes Mellitus, Type 2 279 6 0.022
Macular Degeneration 661 11 0.017
Stroke 1490 17 0.011
Coronary Artery Disease 700 7 0.010
Heart Failure 1127 10 0.009
Cholesterol, LDL 831 7 0.008
Iron deficiency 961 7 0.007
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MAP3K2, and MAP3K4 by GPS2.0 and filtrated by
STRING. RAF1 is known as a T2D gene and a member
of insulin signaling pathway.
PTMs play crucial roles in biological mechanisms, and
PTM-SNPs may influence PTM network regulation and
have effects on associated diseases. From disease-associated
PTM-SNPs, we can find disease-associated PTM networks
regulated by PTM-SNPs that may provide insight into the
mechanisms of disease. Our case studies show the possibi-
lity of using PTM-SNPs, combined with various types of
biological information including known disease genes, drug
targets, protein-protein interaction networks, and pathway
networks, to identify mechanisms underlying disease.
Novel disease-candidate genes can be found from disease-
associated PTM networks assembled from the relations of
PTM enzymes and PTM substrate proteins.
Web interface
Collected PTM-SNPs and disease-associated PTM-SNPs
are provided at the PTM-SNP website. The integrated
PTM-SNP search interface allows users to search PTM-
SNPs by dbSNP rs ID, RefSeq accession (AC), UniProt ID,
or disease terms using the same search interface. Search
results are provided with a PTM-SNP report, protein-level
report or disease-level report, depend on the kind of the
input search terms. When user input a dbSNP rs ID, the
PTM-SNP report is displayed with the general information
about the PTM-SNP including dbSNP rs ID, RefSeq AC,
UniProt ID, residue of SNP, sequence location of PTM
binding site, residue of PTM binding site, relative
sequence location of PTM-SNP from PTM binding site,
PTM name, the type of PTM-SNP, and the disease-asso-
ciation of the PTM-SNP including disease name and p-
value if available. All columns can be easily sorted by click-
ing up/down arrows. In addition to the PTM-SNP infor-
mation, the protein-level report provides all other PTM-
SNPs that have been identified in the same substrate pro-
tein when user input a protein identifier such as RefSeq
AC or UniProt ID. The disease-term search interface pro-
vides the disease-level report including disease-associated
PTM-SNPs with disease name. Researchers can search the
disease-associated PTM-SNPs easily using PTM-SNP web
interface (Figure 2).
Table 6. Type 2 diabetes-associated PTM-SNPs
SNP PTM p-value Gene Known T2D gene
6235 Phosphorylation 1.00E-26 PCSK1
5219 Phosphorylation 7.00E-11 KCNJ11 O
5215 Phosphorylation 5.00E-11 KCNJ11 O
1801214 N-linked Glycosylation 3.00E-08 WFS1 O
1048886 Phosphorylation 3.00E-08 C6orf57
1801282 Phosphorylation 2.00E-06 PPARG O
Figure 2 Schematic illustration of data collection, analysis, and representation of PTM-SNPs.
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Conclusion
In this study, we performed the investigation to associate
PTMs, SNPs and disease using PTM-SNPs and disease-
associated GWAS studies. PTM-SNP is a database based
on dbSNP build 135, dbPTM3, and public GWAS data-
bases of disease-associated SNPs that influence PTMs. In
total, more than 50 kinds of PTMs were considered. PTM
sites involved in signalling pathways such as phosphoryla-
tion, ubiquitination, and acetylation tended to have a
greater proportion of PTM-SNPs than other PTM sites.
Genes that contain disease-associated PTM-SNPs have
been collected and matched against disease genes and
drug targets to elucidate the effects of the SNPs and out
analysis showed that PTM-SNP has higher disease-asso-
ciations as compared with non-PTM-SNPs. We were also
able to identify some of the mechanisms of disease-asso-
ciated SNPs using PTM-SNP data. Researchers can match
their own GWAS datasets with the PTM-SNP database to
find PTM-related effects of the disease-associated SNPs
easily by using the PTM-SNP website. We expect that pro-
vides an insight into unveiling important PTMs involved
in causing diseases and finding novel disease markers.
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